查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046916

生物相似單株抗體市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物相似單株抗體市場預計將從 2025 年的 56.6 億美元大幅成長至 2031 年的 115.4 億美元，複合年成長率為 12.61%。

這些生物類似單株抗體是經過精心研發的、經濟高效的生物製藥，在安全性、純度和療效方面與已獲已通過核准的參考產品高度相似，為癌症和自體免疫疾病等慢性疾病提供了重要的治療選擇。這一市場成長的主要驅動力是主要生物製藥專利到期以及全球對最佳化醫療保健日益成長的需求。例如，美國可及藥品協會在2025年報告中指出，僅生物相似藥一項，到2024年就將為美國醫療保健系統和患者節省202億美元，凸顯了其顯著的經濟貢獻。

市場概覽
預測期 2027-2031
市場規模：2025年 56.6億美元
市場規模：2031年 115.4億美元
複合年成長率：2026-2031年 12.61%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

然而，這些治療方法的廣泛應用面臨著許多挑戰，包括複雜的市場准入障礙和反競爭的合約條款。原廠藥生產商經常採用諸如回扣壁壘和龐大的專利組合等策略，阻礙這些價格更親民的替代療法進入市場並獲得醫保覆蓋，從而減緩其市場佔有率成長，並限制其可能為醫療保健系統帶來的經濟負擔減輕。

市場促進因素

全球生物類似單株抗體市場正受益於有利的法規結構和簡化的核准流程而顯著成長，這些因素有效降低了新進入者的進入門檻。監管機構已實施清晰且有效率的指導方針，使製造商能夠利用比較數據，從而減少將這些複雜的生物製藥推向市場所需的時間和資金投入。這種競爭環境正在推動研發管線的不斷完善，並確保持續供應新的治療選擇，挑戰原廠藥的市場主導地位。根據康德樂公司於2025年3月發布的《生物相似藥十年》報告，這些最佳化的監管流程已促成過去十年中70種新的生物相似藥核准，顯著拓寬了患者和醫療服務提供者的治療選擇。

同時，生物相似藥在醫生和患者中的接受度不斷提高，以及最初對安全性和有效性的擔憂逐漸消除，推動了市場的發展。隨著真實世界數據的累積和宣傳活動的推進，臨床對生物相似藥的信心已與原廠生物製藥不相上下，從而在主要治療領域獲得了較高的應用率。這種「從懷疑到信任」的轉變正在推動銷售量的顯著成長，證實生物相似藥是現代醫療實踐中不可或缺的一部分。根據美國可及藥品協會（Association for Accessible Medicines）於2025年9月發布的《2025年美國非專利藥和生物類似藥節省報告》，該市場已達到33億患者治療日的里程碑，顯示其市場滲透率已十分廣泛。該報告也強調了這種日益成長的接受度所帶來的持續經濟價值，指出自上市以來，生物相似藥已累積節省了562億美元。

市場挑戰

全球生物類似單株抗體市場受到複雜的市場准入障礙和排他性合約條款的嚴重限制，這些因素限制了商業性進入和後續應用。原廠藥生產商通常採用一種被稱為「回扣牆」的策略，即根據銷售提供大幅折扣，但前提是支付方必須給予其原廠藥獨家或優先處方權。這種財務安排促使醫療系統優先選擇價格較高的原廠生物製藥，而非更具成本效益的生物相似藥，從而阻礙了新型單株抗體療法獲得顯著的市場佔有率，儘管這些療法本身俱有成本優勢。

這些限制性策略不僅阻礙了產品的即時普及，也造成了高風險環境，使得製造商不願投資未來的產品線研發。這些壁壘的長期影響顯而易見，針對專利即將到期產品的研發項目數量正在下降。儘管2025年生物相似藥委員會的報告預測，未來十年將有118種生物製藥失去專利保護，但目前僅有12種分子正在研發生物類似藥。開發平臺中如此巨大的缺口凸顯了市場准入受限如何有效地扼殺了整個產業的成長。

市場趨勢

製造商正積極尋求互通性認證，將其作為克服歷史遺留市場准入壁壘的戰略舉措，這些壁壘曾保護原廠生物製藥免受競爭。這一至關重要的監管地位允許在藥房層面進行替代，無需醫療服務提供者的直接干預，從而使生物類似藥開發商能夠繞過原研藥製造商常用的獨家合約和回扣壁壘等策略。透過獲得此認證，企業可以提升價格競爭力，獲得處方藥優先輸入資格，並最終加速市場商品化和普及。獲得此項認證所需的嚴格監管流程凸顯了其重要性。根據康德樂健康公司於2024年2月發布的《2024年生物相似藥報告》，截至2024年初，美國市場上僅有9種生物類似藥獲得了互通性認證，凸顯了其獨特性和在市場滲透方面的戰略價值。

伴隨這些監管舉措，市場正經歷著向皮下給藥和自行注射裝置研發的顯著轉變，這使得治療從臨床環境轉移到患者家中變得更加便捷。這一趨勢標誌著「生技改良藥」的進程，製造商正在重新設計原本用於靜脈注射的單株抗體，使其能夠皮下注射，從而提高便利性、降低系統性醫療保健成本並提高患者遵守用藥。這種差異化策略使生物相似藥公司不僅能夠透過價格競爭來獲取市場佔有率，還能透過提供明顯優於現有標準療法的附加價值來贏得市場佔有率。保險公司近期的措施也印證了這一趨勢的商業性成功。根據Celltrion公司2024年8月的新聞稿，其新推出的皮下注射用英夫利西Infliximab製劑Zymfentra在上市五個月內便在美國保險市場實現了75%的覆蓋率，這表明市場對這些以患者為中心的給藥創新方案有著強勁的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球生物類似單株抗體市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品細分（Infliximab、Rituximab、阿昔單抗、曲妥珠單抗、Adalimumab、貝Bevacizumab、其他）
    • 按應用領域（腫瘤學、慢性/自體免疫疾病、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美生物相似單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物類似單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區生物類似單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物類似單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美生物類似單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球生物相似單株抗體市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories
  • Pfizer Inc.
  • Novartis AG
  • AbbVie, Inc.
  • Coherus Oncology, Inc
  • Biocon Limited
  • Allergan plc.
  • Accord Healthcare limited.
  • Amgen inc.
  • Dr. Reddy's Laboratory Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15878

The Global Biosimilar Monoclonal Antibodies Market is projected to expand significantly, rising from USD 5.66 Billion in 2025 to USD 11.54 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 12.61%. These biosimilar monoclonal antibodies are cost-effective biologic therapies, meticulously developed to be highly similar to their approved reference products in terms of safety, purity, and potency, offering vital treatment options for chronic diseases like cancer and autoimmune conditions. This market growth is primarily driven by the expiry of patents for major biologics and the increasing global demand for optimized healthcare spending. For instance, the Association for Accessible Medicines reported in 2025 that biosimilar medicines alone generated $20.2 billion in savings for the U.S. healthcare system and patients in 2024, underscoring their considerable economic contribution.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.66 Billion
Market Size 2031USD 11.54 Billion
CAGR 2026-203112.61%
Fastest Growing SegmentOncology
Largest MarketNorth America

Nonetheless, the widespread adoption of these therapies is hindered by substantial hurdles, including intricate market access barriers and anti-competitive contracting methods. Original drug manufacturers frequently employ strategies such as rebate walls and extensive patent portfolios to obstruct the market entry or formulary inclusion of these more affordable alternatives, thereby slowing their market share acquisition and limiting the financial relief they could provide to healthcare systems.

Market Driver

The Global Biosimilar Monoclonal Antibodies Market is significantly propelled by supportive regulatory frameworks and streamlined approval pathways, which effectively lower entry barriers for new competitors. Regulatory bodies have implemented clear, efficient guidelines allowing manufacturers to use comparative data, thus reducing the time and capital investment needed to commercialize these intricate biologics. This competitive environment has spurred increased pipeline development, guaranteeing a continuous supply of therapeutic choices that challenge the market dominance of originator products. Cardinal Health's '10 years of biosimilars' report from March 2025 indicates that these optimized regulatory processes have led to the approval of 70 new biosimilars over the last decade, substantially expanding treatment options for both patients and healthcare providers.

Simultaneously, the market benefits from increasing acceptance of biosimilars among physicians and patients, overcoming earlier concerns about their safety and efficacy. As real-world data accumulates and educational efforts advance, clinical confidence in biosimilars has aligned with that of reference biologics, leading to strong adoption rates across key therapeutic areas. This transition from doubt to trust is fostering considerable volume growth, confirming biosimilars as crucial elements in contemporary medical practice. The Association for Accessible Medicines' '2025 U.S. Generic & Biosimilar Medicines Savings Report' from September 2025 reported a milestone of 3.3 billion days of patient therapy delivered to date, signifying extensive market penetration. The report also highlighted that biosimilars have generated cumulative savings of $56.2 billion since their introduction, emphasizing the sustained economic value derived from this heightened acceptance.

Market Challenge

The expansion of the Global Biosimilar Monoclonal Antibodies Market is considerably impeded by complex market access barriers and exclusionary contracting practices, which restrict their commercial entry and subsequent uptake. Original drug manufacturers often employ 'rebate walls,' a tactic where substantial volume-based discounts are contingent upon a payer granting their reference product exclusive or preferred formulary status. This financial arrangement encourages healthcare systems to prioritize more expensive reference biologics over cost-effective biosimilar alternatives, thus preventing new monoclonal antibody therapies from gaining significant market share despite their inherent cost benefits.

Such restrictive strategies not only curtail immediate adoption but also foster a high-risk landscape, deterring manufacturers from investing in future pipeline development. The long-term consequences of these impediments are clearly demonstrated by the dwindling number of development programs for forthcoming off-patent products. As reported by the Biosimilars Council in 2025, despite projections of 118 biologics losing patent exclusivity over the next decade, only 12 molecules currently have biosimilars under development. This considerable void in the development pipeline highlights how limited market access is effectively stalling the overall growth of this sector.

Market Trends

Manufacturers are actively seeking interchangeability designations as a strategic approach to overcome historical market access barriers that have protected originator biologics from competition. This crucial regulatory status permits pharmacy-level substitution without requiring a healthcare provider's direct intervention, thereby allowing biosimilar developers to circumvent exclusionary contracting and rebate wall tactics employed by reference product manufacturers. Achieving this designation enables companies to compete more effectively on price and attain preferred formulary placement, ultimately commoditizing the market and accelerating volume adoption. The rigorous regulatory pathway for this status underscores its importance; as per Cardinal Health's '2024 Biosimilars Report' from February 2024, only 9 biosimilars had gained interchangeability status in the U.S. market by early 2024, highlighting its exclusive nature and strategic value for market penetration.

In parallel with these regulatory efforts, the market is experiencing a significant shift towards subcutaneous administration and the development of self-injection devices, facilitating the transition of therapy delivery from clinical environments to patients' homes. This development signifies a move towards "biobetters," where manufacturers re-engineer intravenous monoclonal antibodies into subcutaneous forms, providing enhanced convenience, lower systemic healthcare costs, and improved patient adherence. This differentiation strategy allows biosimilar companies to secure market share not merely through price competition, but by offering clear, value-added improvements over existing standards of care. The commercial success of this trend is exemplified by recent payer trends; Celltrion's August 2024 press release noted that its newly introduced subcutaneous infliximab formulation, Zymfentra, achieved 75% coverage across the U.S. insurance market within five months of its launch, demonstrating strong demand for these patient-focused delivery innovations.

Key Market Players

  • Abbott Laboratories
  • Pfizer Inc.
  • Novartis AG
  • AbbVie, Inc.
  • Coherus Oncology, Inc
  • Biocon Limited
  • Allergan plc.
  • Accord Healthcare limited.
  • Amgen inc.
  • Dr. Reddy's Laboratory Limited

Report Scope

In this report, the Global Biosimilar Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilar Monoclonal Antibodies Market, By Product

  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
  • Others

Biosimilar Monoclonal Antibodies Market, By Application

  • Oncology
  • Chronic & Autoimmune Diseases
  • Others

Biosimilar Monoclonal Antibodies Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biosimilar Monoclonal Antibodies Market.

Available Customizations:

Global Biosimilar Monoclonal Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilar Monoclonal Antibodies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab, Others)
    • 5.2.2. By Application (Oncology, Chronic & Autoimmune Diseases, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Biosimilar Monoclonal Antibodies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biosimilar Monoclonal Antibodies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Biosimilar Monoclonal Antibodies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Biosimilar Monoclonal Antibodies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Biosimilar Monoclonal Antibodies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Biosimilar Monoclonal Antibodies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Biosimilar Monoclonal Antibodies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Biosimilar Monoclonal Antibodies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Biosimilar Monoclonal Antibodies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biosimilar Monoclonal Antibodies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Biosimilar Monoclonal Antibodies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Biosimilar Monoclonal Antibodies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Biosimilar Monoclonal Antibodies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biosimilar Monoclonal Antibodies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Biosimilar Monoclonal Antibodies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Biosimilar Monoclonal Antibodies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biosimilar Monoclonal Antibodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Novartis AG
  • 15.4. AbbVie, Inc.
  • 15.5. Coherus Oncology, Inc
  • 15.6. Biocon Limited
  • 15.7. Allergan plc.
  • 15.8. Accord Healthcare limited.
  • 15.9. Amgen inc.
  • 15.10. Dr. Reddy's Laboratory Limited

16. Strategic Recommendations

17. About Us & Disclaimer